Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2000, Vol. 5 ›› Issue (4): 344-348.
Previous Articles Next Articles
Received:2000-10-23
Online:2000-12-26
Published:2020-11-27
CLC Number:
| 1 ICH.E 9 Statistical Principles for Clinical trials,1998 2 Hwang IK,Morikawa T.Design issues in noninferior-ity /equivalence trials.Drug Information Journal,1999;33:1 205 3 ICH.E10 Choice of control groups in clinical trials,1998 4 倪宗瓒,主编.医学统计学.第2版.北京:人民卫生出版社,1998:2 1;4 4 5 Chuang-Stein C.Clinical equivalence—a clarification.Drug Information Journal,1999;3 3:1189 6 刘玉秀,洪立基,主编.新药临床研究设计与统计分析.南京大学出版社,1999:88;1 20;125;162 7 黄正南.两个总体均数和两个总体率等价或差别有实际意义的统计推断.数理医药学杂志,1993;6(1):25 8 MaKuch R,Simon R.S ample size requirements for evaluating a conservative therapy.Cancer Treat Rep,1978;62(No.7):1 037 9 Meinert CL,Tonascia S.Clinical Trials —Design,Conduct,and Analysis.Oxford Unversity Press,1986:71 10 刘玉秀,杨友春.临床试验疗效的等效性评价.中国临床药理学与治疗学,1999;4(3):220 11 Morikawa T,Yoshida M.A useful testing strategy in Phase II I trials:Combined test of superiority and test of equivalence.J Biopharm Stat,1995;5(3):297 12 Schuirmann DJ.Bioequiv alence test and two one-sidedt test.J Pha rmacokin Biopha rm,1987;15(1):16 13 Schuirmann DJ.A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of aver agebiovailability.J Pharma-cokin Biopharm,1987;15(6):657 14 国家药品监督管理局第2号令.新药审批办法.1999 |
| [1] | CAO Xuefen, LENG Yufang, HAN Xiaoxia, HOU Xiaoyu, LYU Xingjiao, Janvier NIBARUTA. Tetramethylpyrazine protected against intestinal ischemia-reperfusion injury induced pyroptosis by inhibiting NLRP3 inflammasome activation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1201-1208. |
| [2] | WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218. |
| [3] | ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226. |
| [4] | LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240. |
| [5] | SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262. |
| [6] | CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092. |
| [7] | WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100. |
| [8] | HENG Bingbing, YANG Danfeng, DAI Shuyang, SHANGGUAN Wangning. Propofol relieves the subcutaneous chloroquine-induced pruritus in rats via TRPV1 and CB1 receptors of spinal cord [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1101-1108. |
| [9] | LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978. |
| [10] | YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999. |
| [11] | WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007. |
| [12] | MAO Jun, RONG Yu, LI Yangen, XIONG Dengxi, ZHAO Peng, ZHA Zhengjiang. Effect and safety of flurbiprofen axetil in the analgesic treatment of patients with craniocerebral injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1056-1060. |
| [13] | MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936. |
| [14] | WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727. |
| [15] | LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
